In a major development for allergy treatment, Health Canada has approved the country’s first needle-free epinephrine option, offering a new alternative to traditional auto-injectors like EpiPen.
The newly approved product, Neffy, is a two-milligram nasal spray designed to treat severe allergic reactions, including anaphylaxis. The spray is expected to become available in Canadian pharmacies by summer, following its regulatory clearance on April 9.
Developed and distributed by ALK Canada, Neffy represents a significant shift in emergency allergy care. Unlike traditional injectors that deliver medication through a needle into muscle tissue, the new spray provides epinephrine through the nasal passage, offering a simpler and less intimidating option for patients.
Company officials highlighted that the innovation could benefit millions of Canadians living with life-threatening allergies. The portable design, combined with its ability to withstand temperatures up to 50°C and a shelf life of up to 30 months, makes it especially practical for everyday use.
Clinical trials involving more than 700 participants supported the drug’s approval. According to trial data, no serious side effects were reported. However, mild reactions were observed in cases where a second dose was administered, including throat irritation, headaches, nasal discomfort, and feelings of jitteriness.
Advocacy groups have welcomed the move. Food Allergy Canada praised the approval, noting that introducing more treatment options could reduce reliance on a single product and help prevent supply shortages. The organization has long pushed for greater accessibility and affordability in life-saving allergy medications.
Neffy has already been approved in several international markets, including the United States, Japan, and across Europe. While a lower one-milligram dose is available abroad for younger children, that version has not yet received approval in Canada.
Experts believe this needle-free alternative could improve response times during emergencies, especially for individuals hesitant to use injectable devices. With its arrival, Canada’s allergy treatment landscape is set to become more flexible and patient-friendly.
